Well, I’ve now been sleuthing out these companies publicly, and tracking the performance of these advertising emails, for long enough to take a little look back and see if anything interesting has happened to these firms. The most widely hyped pick of the last week, for Porter Stansberry’s London natural resources bank, is probably too […]
Articles
- Most Relevant
- Most Recent
Boston BiotechWhat is the deal on Boston Biotech (penny stock)? on a melanoma drug breakthrough? There are two other co’s that make the components material/delivery. Boston makes the trigger which is a pill that when taken activates the capture of the melanoma and destroys the cancer cell/melanoma from the inside out.
[ed. note: Michael Jorrin, a longtime medical writer who has earned the nickname “Doc Gumshoe” despite his lack of a stethoscope and medical diploma, is our favorite scribe on all topics health related — we feature his columns every couple weeks here at Stock Gumshoe to help us bring some skepticism and plain speaking to […]
The Value Investing Congress is a two-day conference featuring fairly lengthy, insightful presentations into interesting value investment ideas or bigger picture strategies from some of the most successful hedge fund managers and other value investing “thinkers”. I try to attend every year, and I’m extra delighted that the press and the large corps of bloggers […]
This is one I’m surprised I never got around to doing before — but I just had it sent to me again, and I know I’ve been seeing it fairly consistently since mid-May or so, so I might as well give it a quick writeup here. It was actually teased in the same ad as […]
[ed. note: Michael Jorrin, who I like to call Doc Gumshoe (he’s a longtime medical writer, not a doctor), writes for us on health and medical issues from time to time — his articles generally are not financial in focus, but he has agreed to the same trading restrictions as our other authors, and, as […]
I’ll grant that my headline is meant to be catchy and induce you to read this epistle. Some of you will ask what is ketamine anyway, and most of you will know from the get-go that ketamine, whatever the heck it is, will turn out to be neither a menace nor a miracle, but something […]
[ed note: Michael Jorrin, who I dubbed “Doc Gumshoe,” is a longtime medical writer (not a doctor) who shares his thoughts with Gumshoe readers a couple times a month. He usually does not specifically cover investment ideas, and his words and opinions are his own — his past columns can be found here] Lots of […]
The headline that snagged my attention was this: ‘Thirty-five Thousand Americans Die of Antibiotic-Resistant Infections Each Year” This was based on the Centers for Disease Control’s Antibiotic Resistance Threats in the United States, 2019, which led off with the statement that more than 2.8 million antibiotic-resistant infections occur in the US every year, and more […]
How could I resist this tease? I’m the guy, after all, who needs to stir his little grey cells to recall the name of that beautiful shrub growing at the northeast corner of our house. Eureka, I’ve got it! – it’s called viburnum. I’ve always attributed my lapses in memory to the […]
This here one is an oldie but a goodie — it’s one that I sniffed out back in April, when but a few courageous souls were following the Gumshoe’s exploits. Now that readership here has exploded tenfold or more, and this teaser ad, virtually word for word, has recently started making the rounds again, I […]
Brazil’s economy is finally growing now, a growth that it started getting credit for a few years ago, before the expansion really started — five years ago, it was enough that Brazil under President Lula seemed to have a handle on inflation and a reasonably pro-business government. Now, it’s one of the few large, stable […]
As I type this I’m waiting for the deliveryman to arrive, bringing my new router and computer — one thing I can say about life as the Stock Gumshoe, it’s hell on my laptop. The poor thing is so clogged with spam and has been sent on so many forced marches across the internet as […]
As I type this I’m waiting for the deliveryman to arrive, bringing my new router and computer — one thing I can say about life as the Stock Gumshoe, it’s hell on my laptop. The poor thing is so clogged with spam and has been sent on so many forced marches across the internet as […]
It’s been an unusually active month in the Real Money Portfolio — a couple big sells, several brand new positions, and quite a bit more churn than I usually have. Those transactions have mostly been fairly small, the largest position that I opened or closed was the sale of my sub-2% Facebook position, but that’s […]
I’ve spent the past couple weeks going over my updated opinions on all of the past “Idea of the Month” stocks (or at least, those that haven’t already been dropped from coverage over the years), and I promised to put them all in one big list in order of likingness (yes, I know it’s not […]
[ed. note: Michael Jorrin, who I like to call Doc Gumshoe, is a longtime medical writer (not a doctor) who writes about non-financial health and medical issues for us a couple times a month. Like all of our authors, he chooses his own topics and his words and opinions are his alone. Enjoy!] While working […]
Thoughts About Hurricane Matthew The whole experience of the storm is a perfect analogy with what we are faced with in our financial lives. The idea of an economic storm approaching is a common metaphor or simile that is used by many writers and observers. But is strikes me as something more than a metaphor. […]
Heydy ho, investing friends! I finally wrap up my Annual Review this week by covering the final three names… and I’ve also got a bunch of other updates to share with you, along with one add-on buy and one brand-new holding for the Real Money Portfolio… enjoy! We’ll start with the completion of the annual […]
Since the other part of today’s Friday File is all about a biotech stock tease, I thought I’d start out this week’s look at my Real Money Portfolio stocks in that sector. I avoid the drug developers, for the most part, but health care should be a huge sector and a growing one, in general, […]
[ed note: Michael Jorrin, aka “Doc Gumshoe,” is a medical writer (not a doctor) who shares his thoughts with us once or twice a month. As with all our guest authors, his words and opinions are his own] The stream – or should I say “torrent” – of medical and health-care related news doesn’t seem […]
[ed note: Michael Jorrin is not a doctor but we like to call him “Doc Gumshoe,” he writes non-investment pieces for us about medical hype and health issues from time to time — today he indulged me by taking on a pitch from a health newsletter that caught my eye] The promotional piece – endless […]
The folks at Unconventional Wealth do make an effort to be, well, unconventional — over the years they’ve been pretty aggressive at pitching alternative investment ideas like stamps and other collectibles, but they also do pick the odd stock now and then. And, of course, tease us about it until we feel compelled to find […]
Tom Dyson at the Palm Beach Letter has generally been a relatively low-risk, income-focused guy — he used to run the 12% Letter for Stansberry, before starting Palm Beach Letter with Mark Ford a couple years ago, and for a newsletter guy he does relatively little of the “swing for the fences” stuff. Not that […]
[Ed. Note: Here is the latest contribution from Dr. KSS, who writes for the Irregulars about medicine and biomedical stocks. As always, he has agreed to our trading restrictions and his words and thoughts are his own.] The Belle of the Everglades How To Profit From The Cure First of Two Parts Of the many […]
A pre-emptive tease: no newsletters are yet touting this company, but like many stocks that they do tease, it is small, cheap, almost unknown, and even has the exotic appeal of being Australian. Sort of. At Stock Gumshoe we not only deconstruct pitched stocks, we find teasable stocks before the newsletters do! Let’s return to […]
There’s nothing like a nice, mysterious teaser pitch to greet you upon a return from vacation — I’ve been traveling for ten days or so, returned to the frozen north feeling perhaps slightly grumpy about sitting at my desk instead of at the beach… … but this morning I saw the spiel about Chuck de […]
Greetings once again to all you GummieBulls and GummieBears! The Blind Squirrel here, coming to you this month with some musings on an investment topic I’m sure most of you have heard about in the past. Some may have used it as a basis for building an investment portfolio. And some of you have perhaps given it a […]
[Ed. Note: Dr. KSS, formerly knowns as karmaswimswami on our discussion threads, is here again to talk to the Irregulars about health and medicine and biotech investing ideas. As with all of our guest contributors, he has agreed to our trading restrictions and we have not reviewed, approved or screened his stocks or ideas, and […]
[Ed note: Here is our latest piece from “Doc Gumshoe”, who is a medical writer (not a doctor) who shares his wisdom with us at Stock Gumshoe a couple times a month. As always, Michael’s words and opinions are his own.] Lots of analysts and prognosticators give these cholesterol-lowering agents a big thumbs up. The […]
[ed note: Longtime commenter and reader Dr. KSS, a medical doctor and biotech investor, has agreed to share his thoughts with the Irregulars as one of our guest authors, educating us on health and medicine and sharing some of his biotech investing ideas. He has agreed to the same basic trading restrictions as other paid […]
What is the deal on Boston Biotech (penny stock)? on a melanoma drug breakthrough? There are two other co’s that make the components material/delivery. Boston makes the trigger which is a pill that when taken activates the capture of the melanoma and destroys the cancer cell/melanoma from the inside out.
This discussion is designed to run parallel with the Dr KSS’s article ’Another Hot Australian Biotech: Is Biotron Right for Your Portfolio?’ http://www.stockgumshoe.com/2014/04/microblog-another-hot-australian-biotech-is-biotron-right-for-your-portfolio/ and serves to provide a free general chat room. With luck it will stop the main thread becoming so cluttered with (while often v interesting), random/off topic/thank you posts. If the strategy […]
[Ed. Note: Here is our second installment from Dr. KSS, formerly known as “karmaswimswami” in Gumshoe discussion threads. Dr. KSS has agreed to our trading and disclosure restrictions, and he’s not offering you personal investment or medical advice. As with all of our columnists, we don’t assign topics or opinions and do just a bit of light […]
These are my notes and instant reactions from a presentation at the Value Investing Congress, the notes below might contain errors, paraphrases, incorrect quotes, or misinterpretations. Daniel Miller runs the “Focus five” portfolio at Gabelli, which is designed to overweight a small number of the very best ideas that that money management shop. They look […]
“What tangled webs we mortals weave when first we practice to deceive” – Shakespeare “There’s a sucker born every minute” – P.T. Barnum I know its been only a few days since my March article ran on these cyber-pages, but there is an issue currently unfolding in the market that simply may not wait until […]
[Ed. note: Today we have another article from Jim Skelton, the Blind Squirrel, who writes to share what he learned about investing in his many years in the trenches as a financial advisor. He has agreed to our trading restrictions, the opinions he expresses are his own, and we haven’t reviewed, approved or screened his […]
I bought a few more shares of Altius Minerals today, after looking into them and Sandstorm Gold following some recent reader questions, and I’ll get to that in a moment … but first, I thought I’d toss out a quick Friday File teaser solution for you if you’re curious about what’s being teased in China […]
There’s been a quick burst of interest from Gumshoe readers about Frank Curzio’s latest teaser pitch … and like a fuzzy little puppy, I aim only to please, so we’ll get an answer for you as quickly as we can. OK, not all that quick — we do have our customary blatheration and hemming and […]
Usually when you hear “little-known Canadian stock” you think, “hey, that’s probably some miner lying about their assay samples out of a storefront office in Vancouver” … but this one’s a little different. To start with, it’s not a mining stock, and has nothing to do with gold or tar sands or pipelines or any […]